Why the study?
What are the outcomes of pericardiocentesis and systemic therapy in patients with metastatic breast cancer and pericardial effusions?
What are the outcomes of pericardiocentesis and systemic therapy in patients with metastatic breast cancer and pericardial effusions?
In patients with metastatic breast cancer, pericardiocentesis for cardiac tamponade is lifesaving and often requires no further local treatment when combined with systemic therapy.
Answers are grounded in this paper and cite their sources.
Pericardiocentesis may relieve tamponade in metastatic breast cancer; case series leaves open optimal systemic therapy integration.
Thirty-five patients with metastatic breast cancer and pericardial effusions are described. They were treated with specific endocrine or chemotherapy. Twenty-two (63%) had presented in cardiac tamponade and were rapidly relieved by pericardiocentesis. Eighteen (82%) of these required no further local treatment, 2 obtained relief from a second aspiration and 2 needed additional treatment (intrapericardial bleomycin instillation and surgical pleuropericardial window). The median survival was 13.2 months. No patient relapsed again in the pericardium, suggesting that their prognosis was that of the underlying disease. Cardiac tamponade should be considered in any breathless patient with malignancy. In breast cancer, periocardiocentesis is lifesaving and systemic treatment can usefully prolong life.
No takes yet. Share an insight, caveat, or question.
Woll et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: